Abstract Introduction While no direct comparative data exist for crizotinib in ROS1+ non-small cell lung cancer (NSCLC). studies have suggested clinical benefit with this targeted agent. The objective of this study was to assess the cost-effectiveness of crizotinib compared to standard platinum-doublet chemotherapy for first-line treatment of ROS1+ advanced NSCLC. Methods A Markov mod... https://chefesquipmenters.shop/product-category/side-tables/